If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 211 - 220 of 289
A Phase 1/2 Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemi
Objective
This study is being done to find out more about SC blinatumomab in participants with R/R B-ALL and MRD+ B-ALL. Acute lymphoblastic leukemia is a type of cancer of the blood and bone marrow (the spongy tissue inside bones where blood cells are made).
Protocol No
AMGEN-20180257
Categories
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction - COMET AF
Objective
Trial to Assess Omecamtiv Mecarbil in Patients with HF with Severely Reduced Ejection Fraction
Protocol No
CVC-CYTOKINETICS-COMET-AF
Categories
A Phase 3, Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-Generatio
Objective
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA
Protocol No
MERCK-MK-5684-004
Categories
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
Objective
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RR MM
Protocol No
CARIBOU-CAMMOUFLAGE-CB-011A-MM
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Ac
Objective
Study of quizartinib combined with chemo as maintenance for newly diagnosed AML patients
Protocol No
DAIICHI-AC220-168
Categories
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia
Objective
Study of ziftomenib combinations in patients with R/R AML
Protocol No
KURA-KO-MEN-008
Categories
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Objective
Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML)
Protocol No
ECOG-MM1OA-EA02
Categories
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis
Objective
MaesTTRo-ATTR
Protocol No
CVC-AZ-MAESTTRO-ATTR
Categories
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Objective
Rollover study of LOXO-BTK-18001 for patients with CLL/SLL or non-hodgkin lymphoma
Protocol No
LILLY-J2N-MC-JZNY
Categories